Cryoport
CYRX
17.35
-0.45
-2.53%
Cryoport
US · CYRX
#3336 by market cap
Listed 2015
17.35
-0.45
-2.53%
Live - 5344 symbols - heartbeat 264s ago
· 2026-10-08 09:16
Pre-market
17.19
-0.93%
After-hours
17.35
0.00%
Overnight
17.30
-0.29%
- Market cap
- 878.76M
- P/E (TTM)i
- -19.28
- P/Bi
- 1.98
- EPSi
- 1.40
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on CYRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.22, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +12.38% YoY
Margins
- Gross margin
- 47.14%
- Operating margin
- -20.89%
- Net margin
- 39.90%
Key ratios & quality
- Enterprise valuei
- 658.45M
- Altman Z-Scorei
- 1.22
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.63M | 33.94M | 78.70M | 222.61M | 237.28M | 168.66M | 156.77M | 176.18M |
| Gross profit | 10.24M | 17.35M | 36.33M | 96.58M | 103.87M | 75.33M | 69.66M | 83.05M |
| Selling & admin expenses | 17.04M | 31.29M | 56.86M | 97.56M | 120.06M | 108.26M | 109.81M | 102.82M |
| Research & development | 1.84M | 3.74M | 9.48M | 16.84M | 15.72M | 18.04M | 17.71M | 17.04M |
| Operating profit | -8.64M | -17.68M | -30.01M | -17.83M | -31.90M | -50.97M | -57.86M | -36.81M |
| Pretax profit | -9.54M | -18.27M | -32.74M | -273.84M | -35.09M | -84.21M | -104.35M | -32.17M |
| Tax | 19.95K | 62.00K | -45.00K | 1.69M | 2.24M | 345.00K | 359.00K | 1.80M |
| Net profit | -9.56M | -18.33M | -32.69M | -275.53M | -37.33M | -99.59M | -114.76M | 78.30M |
| Basic EPS | 0 | -1 | -2 | -6 | -1 | -2 | -2 | 1 |
| Diluted EPS | -0.34 | -0.55 | -1.94 | -6.18 | -0.93 | -2.21 | -2.49 | 1.40 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 41.04M | 45.45M | 44.23M | 45.45M | 47.80M | 48.97M |
| Gross profit | 18.64M | 21.38M | 21.33M | 21.71M | 21.91M | 22.82M |
| Selling & admin expenses | 21.90M | 26.91M | 26.73M | 27.28M | 27.62M | 28.01M |
| Research & development | 3.93M | 4.12M | 4.52M | 4.47M | 3.91M | 4.85M |
| Operating profit | -7.19M | -9.65M | -9.93M | -10.03M | -9.61M | -10.04M |
| Pretax profit | -6.50M | -11.74M | -6.53M | -7.40M | -9.32M | -7.75M |
| Tax | 234.00K | 274.00K | 165.00K | 1.13M | 108.00K | 505.00K |
| Net profit | -11.98M | 108.87M | -6.94M | -11.64M | -10.54M | -8.26M |
| Basic EPS | 0 | 2 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.28 | 2.13 | -0.18 | -0.27 | -0.25 | -0.20 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 51.77M | 102.97M | 147.16M | 693.52M | 604.18M | 535.11M | 341.57M | 476.17M |
| Cash & ST investments | 47.26M | 94.30M | 93.32M | 628.80M | 523.32M | 456.76M | 250.60M | 411.21M |
| Inventory | 220.51K | 474.00K | 10.54M | 16.50M | 27.68M | 26.21M | 21.48M | 23.19M |
| Total assets | 56.62M | 135.87M | 552.41M | 1.11B | 1.04B | 957.74M | 703.49M | 764.99M |
| Total current liabilities | 3.06M | 5.46M | 35.02M | 42.65M | 40.85M | 45.61M | 64.56M | 219.02M |
| Short-term debt | 23.19K | 691.00K | 2.29M | 3.60M | 3.91M | 5.81M | 18.16M | 189.81M |
| Long-term debt | 14.71M | -- | 116.26M | 405.26M | 407.06M | 379.89M | 185.03M | 1.09M |
| Total liabilities | 18,073,532.00 | 9,592,000.00 | 169,707,000.00 | 471,142,000.00 | 482,908,000.00 | 468,721,000.00 | 301,594,000.00 | 262,351,000.00 |
| Total equity | 38.55M | 126.28M | 382.70M | 641.83M | 555.84M | 489.02M | 401.90M | 502.64M |
| Retained earnings | -140.99M | -159.32M | -192.01M | -467.54M | -542.83M | -642.42M | -757.18M | -688.88M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 411.28M | 489.49M | 484.84M | 476.17M | 470.54M | 460.20M |
| Cash & ST investments | 244.03M | 425.98M | 421.31M | 411.21M | 403.63M | 396.69M |
| Inventory | 23.34M | 23.04M | 23.33M | 23.19M | 21.75M | 21.51M |
| Total assets | 699.84M | 773.93M | 774.33M | 764.99M | 763.61M | 756.20M |
| Total current liabilities | 74.03M | 30.15M | 30.75M | 219.02M | 224.87M | 221.04M |
| Short-term debt | 18.48M | 4.32M | 4.55M | 189.81M | 189.61M | 190.23M |
| Long-term debt | 185.33M | 185.83M | 186.09M | 1.09M | 1.03M | 985.00K |
| Total liabilities | 301,033,000.00 | 258,536,000.00 | 261,057,000.00 | 262,351,000.00 | 268,620,000.00 | 265,505,000.00 |
| Total equity | 398.81M | 515.39M | 513.27M | 502.64M | 494.99M | 490.70M |
| Retained earnings | -769.16M | -668.24M | -675.24M | -688.88M | -699.43M | -707.68M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.35M | -1.32M | -14.87M | 8.13M | -1.85M | -757.00K | -16.32M | -8.58M |
| Depreciation & amortization | 857.94K | 2.42M | 9.87M | 20.25M | 22.77M | 27.49M | 30.76M | 27.71M |
| Free cash flow | -6.31M | -6.73M | -24.54M | -16.88M | -26.05M | -45.66M | -37.59M | -28.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 17.81M | 68.81M | 28.16M | 269.83M | -37.96M | 0 | 0 | -10.01M |
| Ending cash balance | 37.33M | 47.24M | 36.87M | 139.10M | 36.60M | 46.35M | 45.29M | 250.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.34M | -7.35M | 2.19M | 919.00K | 3.74M | 1.13M |
| Depreciation & amortization | 7.65M | 7.30M | 6.42M | 6.36M | 6.40M | 6.59M |
| Free cash flow | -8.42M | -13.55M | -2.09M | -4.03M | -6.55M | -8.68M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -3.75M | -2.01M | -- | -- |
| Ending cash balance | 47.36M | 243.42M | 255.81M | 250.49M | 272.91M | 269.27M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -33.87 | -22.24 | -29.65 | -56.10 | -7.76 | -21.51 | -29.57 | 16.98 |
| ROA %i | -24.86 | -19.05 | -21.80 | -34.07 | -4.21 | -10.78 | -14.78 | 9.57 |
| ROIC %i | -22.11 | -18.80 | -22.58 | -35.72 | -3.98 | -11.15 | -15.97 | 11.02 |
| 5-year avg ROE %i | -- | -- | -80.00 | -41.78 | -29.92 | -27.45 | -28.92 | -19.59 |
| EBIT margin %i | -48.23 | -49.80 | -38.35 | -120.91 | -12.20 | -40.23 | -47.89 | -16.92 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 16.91 | 18.85 | 4.20 | 16.26 | 14.79 | 11.73 | 5.29 | 2.17 |
| Quick ratioi | 16.59 | 18.57 | 3.56 | 15.67 | 13.88 | 10.94 | 4.27 | 2.03 |
| Debt / assetsi | 26.08 | 3.53 | 23.70 | 38.37 | 41.96 | 43.44 | 34.48 | 30.16 |
| LT debt / equityi | 38.25 | 3.25 | 33.86 | 67.05 | 80.36 | 88.64 | 61.04 | 8.89 |
| Interest coveragei | -136.69 | -12.37 | -11.79 | -57.40 | -4.71 | -17.05 | -26.62 | -12.63 |
| Revenue CAGR (3Y) %i | 54.90 | 64.11 | 87.42 | 124.68 | 91.21 | 28.93 | -11.03 | -9.45 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -28.73 | 15.90 | 14.73 | 16.98 | 17.64 | -9.85 |
| ROA %i | -14.10 | 8.28 | 8.57 | 9.57 | 9.80 | -5.93 |
| ROIC %i | -15.46 | 9.40 | 9.85 | 11.02 | 11.36 | -6.38 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -44.77 | -15.83 | -20.01 | -16.92 | -17.92 | -15.49 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.56 | 16.24 | 15.77 | 2.17 | 2.09 | 2.08 |
| Quick ratioi | 3.68 | 15.24 | 14.84 | 2.03 | 1.97 | 1.96 |
| Debt / assetsi | 34.67 | 29.53 | 29.81 | 30.16 | 30.18 | 30.68 |
| LT debt / equityi | 61.84 | 46.99 | 47.85 | 8.89 | 9.07 | 9.40 |
| Interest coveragei | -30.43 | -13.48 | -20.01 | -12.63 | -14.83 | -13.69 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Life Sciences Services is the largest reported line at 58.57% of revenue, across 3 reported segments.
- Life Sciences Products follows at 43.99%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Life Sciences Services58.57%
Life Sciences Products43.99%
Quote time 2026-10-08 09:16:57 · For reference only, not investment advice and not tailored to your situation.